On November 2, 2026, the FDA issued its final guidance, Potency Assurance for Cellular and Gene Therapy Products, outlining a risk-based approach to ensuring th...
Continue reading
AI systems have started producing results on open problems in mathematics, and mathematicians are paying attention. In the most recent episode of The Genetics P...
Continue reading
.png)
The FDA's draft guidance on individualized human genome editing products, issued on 27 October 2026, proposes a pathway that could allow a single biologics lice...
Continue reading
In the latest episode of The Genetics Podcast, host Patrick Short speaks with Dr. Sekar (Sek) Kathiresan, CEO of Verve Therapeutics and SVP, Head of Obesity Res...
Continue reading
New findings presented at ASHG 2026 show how population genomic screening is identifying genetic risk at scale and changing preventive care. For sponsors develo...
Continue reading
In the latest episode of The Genetics Podcast, Patrick Short is joined by Dr. Luke Pilling, Senior Lecturer in Genetic Epidemiology at the University of Exeter....
Continue reading
Beam Therapeutics' early clinical results highlight the promise of mutation-specific therapies. But as treatments become more genetically targeted, they also ra...
Continue reading
In the latest episode of The Genetics Podcast, host Patrick Short speaks with Dr. James Zou, Associate Professor of Biomedical Data Science at Stanford Universi...
Continue reading
An FDA notice seeking public input is under review at the Office of Management and Budget, according to a Citeline report on October 12, 2026. The notice sugges...
Continue reading
Genetic medicines are changing who cardiovascular trials need to find. Eligibility is increasingly defined by a genotype or a biomarker level, and the people wh...
Continue reading